CTOs on the Move

Secura Bio

www.securabio.com

 
Secura Bio™ is a pharmaceutical company committed to giving patients access to innovative therapies. Headquartered in Henderson, Nevada, Secura Bio™ has operations in the U.S. and Offices in San Diego.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.securabio.com
  • 1887 Whitney Mesa Drive #1050
    Henderson, NV USA 89014
  • Phone: 858.251.1414

Executives

Name Title Contact Details

Funding

Secura Bio raised $55M on 03/05/2019
Secura Bio raised $90M on 03/05/2019

Similar Companies

Iconix Biosciences

Iconix Biosciences is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cornerstone Family Healthcare

Cornerstone Family Healthcare is a comprehensive Hudson Valley medical care provider, offering urgent care, preventative care, womens health, pediatrics and more.

Ratiopharm Inc

Ratiopharm Inc is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Louisiana Wholesale Drug Company

Louisiana Wholesale Drug Company is a Ruston, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

X4 Pharmaceuticals

X4 Pharmaceuticals (Nasdaq: XFOR) is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company`s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4`s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is also planning to commence clinical trials of mavorixafor in Severe Congenital Neutropenia (SCN) and Waldenström`s macroglobulinemia (WM) in 2019. The company was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria.